Multiple SclerosisPhase 4NCT00423527
Levetiracetam in Central Pain in Multiple Sclerosis(MS)
A Phase 4 study testing levetiracetam in people with Multiple Sclerosis, run by Odense University Hospital at 1 site in Denmark.
Trial summary
Multiple sclerosis is often associated with pain. There is no standard treatment of this type of pain. Levetiracetam is a new anticonvulsant and it is the hypothesis that it could relieve central pain in multiple sclerosis. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Multiple Sclerosis
- What is being tested?
- levetiracetam
- Type of treatment
- Pill or oral medicine
- How many people
- 30 participants
- Where
- 1 siteDenmark
- Study dates
- Jan 2007to Jan 2009
- Phase
- Phase 4
- Are there results?
- None posted in the registry
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- ms diagnosis verified
- age > 18 years
- central pain symptoms for more than 3 months
- central pain diagnosis confirmed by neurological examination
- adequate anticonceptive treatment for women with child bearing potential
- informed consent
- baseline pain of more than 4 on numeric rating scale
Who cannot join
- other cause of pain
- previous allergic reaction towards levetiracetam
- known adverse drug reaction on levetiracetam
- pregnancy
- severe disease
- inability to follow study protocol
- treatment with antidepressants, other anticonvulsants or opioids
Trial locations and contacts
1 site in 1 country.
Denmark1 site
Department of Neurology, Odense University Hospital
Odense C, DK-5000
About this study
Official title: Double-blind, Randomised,Placebo-controlled Trial of Levetiracetam in Central Pain in Multiple Sclerosis
Multiple sclerosis is often associated with pain. There is no standard treatment of this type of pain. Levetiracetam is a new anticonvulsant and it is the hypothesis that it could relieve central pain in multiple sclerosis. This is a randomised, double-blind, placebo-controlled, cross-over trial on the effect of levetiracetam 3000 mg daily on pain in multiple sclerosis.
- Conditions
- Multiple Sclerosis
- Being tested
- levetiracetam
- Keywords
- multiple sclerosis, central pain, levetiracetam
- Medical subject headings
- Multiple Sclerosis
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
levetiracetamDrug
Levetiracetam tablets 500 mg, total daily dose 3000 mg
What is being measured
The primary outcome is the main question the study is designed to answer.
Pain relief rated on a 0 to 10 point numeric rating scale (median value for last treatment week of each period)
Measured: Weekly
Secondary outcomes (9)
Pain rated on a 0 to 10 point numeric rating scale
Measured: Daily
Pain subtypes rated on the same scale.
Measured: Daily
Brush-evoked pain
Measured: Baseline and end of each treatment period
Pin-prick-evoked pain
Measured: Daily
Cold-evoked pain
Measured: Daily
Health related quality of life (SF36)
Measured: Baseline and end of each treatment period
Pain related sleep disturbance
Measured: Daily
Use of escape medication
Measured: Daily
Muscle spasms as measured on 2 different scales
Measured: Baseline and end of each treatment period
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted18 Jan 2007 (estimated)
- Study startJan 2007
- Primary completionJan 2009
- Study completionJan 2009
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Multiple SclerosisStudies of the same condition, open and under way.
- More trials run by Odense University HospitalThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 4
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 30 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Odense University Hospital
- Sponsor type
- University, hospital or other
- Investigators
- Søren H Sindrup, MD, Principal investigator, Department of Neurology, Odense Unviersity Hospital
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT00423527
- Sponsor's protocol ID
- keppra3
- Status last verified
- Jan 2007
- First submitted
- 16 Jan 2007
- Last updated
- 18 Dec 2009
- Results posted
- No
Study at a glance
From the registry record, last updated by the sponsor on 18 Dec 2009. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Double-blind, Randomised,Placebo-controlled Trial of Levetiracetam in Central Pain in Multiple Sclerosis
- ClinicalTrials.gov ID
- NCT00423527
- Acronym / sponsor ID
- keppra3
- Conditions
- Multiple Sclerosis
- Keywords
- multiple sclerosis, central pain, levetiracetam
- Phase
- Phase 4
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 30 participants (estimated)
- Lead sponsor
- Odense University HospitalUniversity, hospital or other
- Study start
- Jan 2007
- Primary completion
- Jan 2009 (actual)
- Study completion
- Jan 2009 (actual)
- First posted
- 18 Jan 2007 (estimated)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Multiple sclerosis is often associated with pain. There is no standard treatment of this type of pain. Levetiracetam is a new anticonvulsant and it is the hypothesis that it could relieve central pain in multiple sclerosis. This is a randomised, double-blind, placebo-controlled, cross-over trial on the effect of levetiracetam 3000 mg daily on pain in multiple sclerosis.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Crossover
- Masking
- Triple blind (participant, investigator, outcomes assessor)
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (7 listed)
- ms diagnosis verified
- age > 18 years
- central pain symptoms for more than 3 months
- central pain diagnosis confirmed by neurological examination
- adequate anticonceptive treatment for women with child bearing potential
Key exclusion criteria (7 listed)
- other cause of pain
- previous allergic reaction towards levetiracetam
- known adverse drug reaction on levetiracetam
- pregnancy
- severe disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| levetiracetamLevetiracetam tablets 500 mg, total daily dose 3000 mg | Drug | – |
Primary outcome
Pain relief rated on a 0 to 10 point numeric rating scale (median value for last treatment week of each period)
Time frame: Weekly
9 secondary outcomes
Pain rated on a 0 to 10 point numeric rating scale
Time frame: Daily
Pain subtypes rated on the same scale.
Time frame: Daily
Brush-evoked pain
Time frame: Baseline and end of each treatment period
Pin-prick-evoked pain
Time frame: Daily
Cold-evoked pain
Time frame: Daily
Health related quality of life (SF36)
Time frame: Baseline and end of each treatment period
Pain related sleep disturbance
Time frame: Daily
Use of escape medication
Time frame: Daily
Muscle spasms as measured on 2 different scales
Time frame: Baseline and end of each treatment period
Results and safety
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 18 Dec 2009.
Related trials for Multiple Sclerosis
RecruitingPhase 2
Metformin as an add-on or Monotherapy in Treatment of Aging People With Multiple Sclerosis (MS)
Multiple Sclerosis
RecruitingObservational study
Pain Phenotypes in Individuals With Multiple Sclerosis
Multiple Sclerosis, Chronic Pain
Not yet recruiting
Evaluating the Effect of the Zeen Mobility Device on Clinical Practicality, Safety, and Impact (Via Assessments of Walking, Standing Tolerance, Balance, Endurance, Effort, and Participation in Daily Tasks) in an Outpatient Rehabilitation Setting for Individuals With Mobility Impairments.
Stroke, Parkinson's Disease (PD)
RecruitingPhase 3
Dalfampridine Combined With Physical Therapy for Mobility Impairment in Multiple Sclerosis
Multiple Sclerosis
RecruitingPhase 2
Targeting Agonists of Glucagon-like Peptide-1 Receptor for Multiple Sclerosis
Multiple Sclerosis
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Søren H Sindrup, MD principal investigator
Department of Neurology, Odense Unviersity Hospital
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 4 study testing levetiracetam in people with Multiple Sclerosis, run by Odense University Hospital at 1 site in Denmark.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 7 inclusion and 7 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 18 Dec 2009. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Denmark. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 4 studies take place after a treatment is approved, to learn more about its long-term benefits and risks in everyday use.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Pain relief rated on a 0 to 10 point numeric rating scale (median value for last treatment week of each period) (time frame: Weekly). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 18 Dec 2009.